Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.

医学 无容量 耐受性 易普利姆玛 围手术期 肝细胞癌 临床终点 内科学 外科 佐剂 肿瘤科
作者
Ahmed Omar Kaseb,Elshad Hasanov,Hop Sanderson Tran Cao,Lianchun Xiao,Jean-Nicolas Vauthey,Sunyoung S Lee,Betul Gok Yavuz,Yehia I Mohamed,Aliya Qayyum,Sonali Jindal,Fei Duan,Sreyashi Basu,Shalini S Yadav,Courtney Nicholas,Jing Jing Sun,Kanwal Pratap Singh Raghav,Asif Rashid,Kristen Carter,Yun Shin Chun,Ching-Wei David Tzeng,Divya Sakamuri,Li Xu,Ryan Sun,Vittorio Cristini,Laura Beretta,James C Yao,Robert A Wolff,James Patrick Allison,Padmanee Sharma
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (3): 208-218
标识
DOI:10.1016/s2468-1253(21)00427-1
摘要

Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed to evaluate the safety and tolerability of perioperative immunotherapy in resectable hepatocellular carcinoma.In this single-centre, randomised, open-label, phase 2 trial, patients with resectable hepatocellular carcinoma were randomly assigned (1:1) to receive 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery at 6 weeks) followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for 2 years, or 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery) plus one dose of 1 mg/kg of ipilimumab intravenously concurrently with the first preoperative dose of nivolumab, followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for up to 2 years plus 1 mg/kg of ipilimumab intravenously every 6 weeks for up to four cycles. Patients were randomly assigned to the treatment groups by use of block randomisation with a random block size. The primary endpoint was the safety and tolerability of nivolumab with or without ipilimumab. Secondary endpoints were the proportion of patients with an overall response, time to progression, and progression-free survival. This trial is registered with ClinicalTrials.gov (NCT03222076) and is completed.Between Oct 30, 2017, and Dec 3, 2019, 30 patients were enrolled and 27 were randomly assigned: 13 to nivolumab and 14 to nivolumab plus ipilimumab. Grade 3-4 adverse events were higher with nivolumab plus ipilimumab (six [43%] of 14 patients) than with nivolumab alone (three [23%] of 13). The most common treatment-related adverse events of any grade were increased alanine aminotransferase (three [23%] of 13 patients on nivolumab vs seven [50%] of 14 patients on nivolumab plus ipilimumab) and increased aspartate aminotransferase (three [23%] vs seven [50%]). No patients in either group had their surgery delayed due to grade 3 or worse adverse events. Seven of 27 patients had surgical cancellations, but none was due to treatment-related adverse events. Estimated median progression-free survival was 9·4 months (95% CI 1·47-not estimable [NE]) with nivolumab and 19·53 months (2·33-NE) with nivolumab plus ipilimumab (hazard ratio [HR] 0·99, 95% CI 0·31-2·54); median time to progression was 9·4 months (95% CI 1·47-NE) in the nivolumab group and 19·53 months (2·33-NE) in the nivolumab plus ipilimumab group (HR 0·89, 95% CI 0·31-2·54). In an exploratory analysis, three (23%) of 13 patients had an overall response with nivolumab monotherapy, versus none with nivolumab plus ipilimumab. Three (33%) of nine patients had a major pathological response (ie, ≥70% necrosis in the resected tumour area) with nivolumab monotherapy compared with three (27%) of 11 with nivolumab plus ipilimumab.Perioperative nivolumab alone and nivolumab plus ipilimumab appears to be safe and feasible in patients with resectable hepatocellular carcinoma. Our findings support further studies of immunotherapy in the perioperative setting in hepatocellular carcinoma.Bristol Myers Squibb and the US National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
浅浅殇完成签到,获得积分10
1秒前
2秒前
4秒前
滴答发布了新的文献求助10
7秒前
高高的天亦完成签到 ,获得积分10
8秒前
星空完成签到 ,获得积分10
9秒前
文艺的青旋完成签到 ,获得积分10
9秒前
青黛完成签到 ,获得积分10
16秒前
大橙子发布了新的文献求助10
20秒前
领导范儿应助科研通管家采纳,获得10
21秒前
量子星尘发布了新的文献求助10
25秒前
明钟达完成签到 ,获得积分10
33秒前
byyyy完成签到,获得积分10
36秒前
高高的哈密瓜完成签到 ,获得积分10
40秒前
Rondab应助橙汁采纳,获得10
43秒前
读书的时候完成签到,获得积分10
45秒前
颜云尔完成签到,获得积分10
56秒前
孤独雨梅完成签到,获得积分10
59秒前
woobinhua完成签到 ,获得积分10
59秒前
雪落你看不见完成签到,获得积分10
1分钟前
十月天秤完成签到,获得积分0
1分钟前
依文完成签到,获得积分20
1分钟前
ymr完成签到 ,获得积分10
1分钟前
哦哦哦完成签到 ,获得积分10
1分钟前
jzmupyj完成签到,获得积分10
1分钟前
大橙子发布了新的文献求助10
1分钟前
xdlongchem完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
小梦完成签到,获得积分10
1分钟前
xuhang完成签到,获得积分10
1分钟前
ZSHAN完成签到,获得积分10
1分钟前
美满的机器猫完成签到,获得积分10
1分钟前
王小磊完成签到,获得积分10
1分钟前
谢花花完成签到 ,获得积分10
1分钟前
1分钟前
瓦罐完成签到 ,获得积分10
1分钟前
扁舟灬完成签到,获得积分10
1分钟前
Cpp完成签到 ,获得积分10
1分钟前
贤惠的老黑完成签到 ,获得积分10
1分钟前
ame1120发布了新的文献求助10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022